EcoDrugPlus

Protein Kinase D1

Ensembl ID : ENSBGRG00000006007
Gene Symbol: PRKD1
1 Cross references
214 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSBGRG00000013689
Gene Symbol: PRKD3
1 Cross references
274 Possible Orthologues:

Protein Kinase Camp-Activated Catalytic Subunit Alpha

Ensembl ID : ENSBGRG00000023559
Gene Symbol: PRKACA
1 Cross references
288 Possible Orthologues:

Protein Kinase Camp-Activated Catalytic Subunit Beta

Ensembl ID : ENSBGRG00000001167
Gene Symbol: PRKACB
1 Cross references
304 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSBGRG00000002633
Gene Symbol: PPP3CA
1 Cross references
232 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSBGRG00000024620
Gene Symbol: PTK2
1 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSBGRG00000000804
Gene Symbol: PTK2B
1 Cross references
213 Possible Orthologues:

Protein Tyrosine Kinase 6

Ensembl ID : ENSBGRG00000016608
Gene Symbol: PTK6
1 Cross references
174 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSBGRG00000019798
Gene Symbol: PTPN11
1 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSBGRG00000009450
Gene Symbol: PTPRB
1 Cross references
268 Possible Orthologues:

Purine Nucleoside Phosphorylase

Ensembl ID : ENSBGRG00000026534
Gene Symbol: PNP
1 Cross references
119 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSBGRG00000005034
Gene Symbol: P2RX3
1 Cross references
272 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).